Loading asset research
Q3 2026 earnings · Nov 5
Avalo Therapeutics Inc. Common Stock
AVTXNasdaq · USD · StocksQuote as of · Exchange session not verified$15.48
+1.18%
Today
AVTX
Loading 1D prices…
Market cap
$843.1M
Volume
1.9M
52w high
$24.2752w low
$10.70Company profile
Avalo Therapeutics Inc. Common Stock
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Wayne, PA, United States
Employees
33
Fiscal year end
1231
CIK
1534120
Session & valuation
Open$15.24
Previous close$15.30
Day high$16.10
Day low$14.58
30-day avg. volume966.1K
Outstanding shares53.6M
Diluted EPS-$5.84
Latest annual period
P/E (trailing)-2.65
P/E (forward)-5.73
Price / book1.85
Beta0.79
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| IMMXImmix Biopharma Inc. Common Stock | $837M | $0.00 | — | -$0.89 | -7.42% | Buy |
| OBXObsidian Therapeutics Inc. Common Stock | $828.4M | $0.00 | — | -$1.63 | -15.73% | Buy |
| LXRXLexicon Pharmaceuticals Inc. Common Stock | $827.6M | $49.8M | -101.08% | -$0.14 | -11.41% | Buy |
| GERNGeron Corporation Common Stock | $809.5M | $183.9M | -45.41% | -$0.13 | +2.02% | Hold |
| CYRXCryoPort Inc. Common Stock | $881.3M | $176.2M | +44.44% | $1.40 | -0.46% | Buy |